Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: A randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas

British Journal of Cancer

Volumn 107, Issue 3, 2012, Pages 411-416

  Meng, Z ^a,b   Garrett, C R ^c   Shen, Y ^a,b   Liu, L ^a,b   Yang, P ^c   Huo, Y ^a,b   Zhao, Q ^b   Spelman, A R ^c   Ng, C S ^c   Chang, D Z ^c,d   Cohen, L ^c  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d DZC Virginia Oncology Associaties   (United States)

Author keywords

gemcitabine; huachansu; pancreatic cancer; traditional Chinese medicine

Indexed keywords

CHINESE DRUG; GEMCITABINE; HUACHANSU; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER SURVIVAL; CHINESE MEDICINE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SKIN TOXICITY; THROMBOCYTOPENIA; TOXICITY TESTING; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; AMPHIBIAN VENOMS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANURA; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD;

EID: 84864377344     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.283     Document Type: Article

References (29)

1. Boik J (2001) Using natural compounds in combination. In Natural Compounds in Cancer Therapy, Farnell S (ed), pp 4-5. Oregon Medical Press: Princeton, MN Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events. version 3.0. Department of Health and Human Services, National Institutes of Health: National Cancer Institute. Available from: URL: http://www.eortc.be/services/doc/ctc/ctcaev3.pdf (accessed 20 December 2011)
2. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, Eckberg K, Lloyd S, Purl S, Blendowski S, Goodman M, Barnicle M, Stewart I, McHale M, Bonomi P, Kaplan E, Taylor S, Thomas CR, Harris J (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11: 570-579
3. Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, Engstrom MC (2000) Assessing symptom distress in cancer: The M. D. Anderson Symptom Inventory. Cancer 89(7): 1634-1646
4. Cox DR (1972) Regression models and life tables. J R Stat Soc B 34: 187-220
5. Cragg GM, Schepartz SA, Suffness M (1993) The taxol supply crisis: new NCI policies for handling the large scale production of novel natural product anticancer and anti-HIV agents. J Natl Cancer Prod 56: 1657-1668
6. Cragg GM, Newman DJ, Sander KM (1997) Natural products in drug discovery and development. J Natl Cancer Prod 60: 52-60
7. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27: 5513-5518
8. Cuo XD, Cuei YA, Wang JH, Qin S, Chen HY (2003a) The effect of cinobufacini on human gastric neoplasm cell line MGC-80-3. Chinese Clin Oncol 8: 33-37
9. Cuo XD, Cuei YA, Qin S, Chen HY, Wang JH (2003b) Effect of cinobufacini on tumor cell cycle and expression of bcl-2 protein. Mod J Intergrated Tradit Chin West Med 12: 567-568
10. Di Marco M, Di Cicilia R, Macchini M, Nobili E, Vecchiarelli S, Brandi G, Biasco G (2010) Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? Oncol Rep 23: 1183-1192
11. Fisher RA (1950) Statistical Methods for Research Workers (11th edn), pp 107. Hafner Publishing Company: New York, NY
12. Guan J, Zhao XH, Jiang BS, Chen ZW, Qin QY (1993) Preliminary study on the antitumor mechanism of cinobufacini injection. J Penfu Med College 18: 78-81
13. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. Am Stat Assoc 53: 457-481
14. Liu BR, Xu XL, Liu WC, Meng XZ (2002) Effects of four extracts of traditional Chinese medicinal materials on the proliferation of human lung cancer A549 cell line. Chinese Pharmacol Bull 18: 94-96
15. Meng Z, Yang P, Shen Y, Bei W, Zhang Y, Ge Y, Newman RA, Cohen L, Liu L, Thornton B, Chang DZ, Liao Z, Kurzrock R (2009) Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer 115(22): 5309-5318
16. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. National Cancer Institute of Canada Clinical Trials Group (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966
17. Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J (2009) Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol 27: 5660-5669
18. Shao GR (2001) The clinical observation on huachansu treatment in late stage lung cancer. Tianjin J Trad Chinese Med 18: 46-47
19. Su YH, Nu X (2001) Evaluation of pharmacodynamic effect of pharmaceutical agents of Chan Su. J Beijing Univ TCM 24: 51-54
20. Su YH, Huang XQ, Zhang DZ, Zhang YN, Xie JM, Linh CQ (2003) HPLC separation and determination of bufadienolide in cinobufacini injection. Chin Tradit Pat Med 25: 24-27
21. Sun GL, Wang ZY, Chen SY (1984) The preliminary study of Chansu on immune function. J Chinese Interg Med 4: 297-299
22. Therasse P, Arbuck S, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 92: 205-216
23. Wang JZ, Yan JG, Zhang J, Liu JC (2000) Studies on the analgestic effect of cinobufacini injection and its mechanism. J Linyi Medical College 22: 81-84
24. Wang XS, Wang Y, Guo H, Mendoza TR, Hao XS, Cleeland CS (2004) Chinese version of the M. D. Anderson Symptom Inventory: validation and application of symptom measurement in cancer patients. Cancer 101: 1890-1891
25. Wei X, Chen CZ, Wu T, Yang X, Liu G (2007) WITHDRAWN: Medicinal herbs for esophageal cancer. Cochrane Database Syst Rev 18(3): CD004520
26. Yang ZH, Zhang MY (1987) The effect of huachansu and its fraction Bf1, bF2 on immune function in mice. Shanghai J Immune 7: 96-98
27. Yu CL, Fielding R, Chan CL, Tse VK, Choi PH, Lau WH, Choy DT, O SK, Lee AW, Sham JS (2000) Measuring quality of life of Chinese cancer patients: a validation of the Chinese version of the Functional Assessment of Cancer Therapy-General (FACT-G) scale. Cancer 88: 1715-1727
28. Yu SH, Ling CQ (2001) Clinical effect of huachansu in treatment of liver cancer. Acad J Sec Mil Med Univ 22: 83-84
29. Zhang ZY, Zhang KH, Wang ZW, Zhu JQ, Zhu ZH, Huang DQ (1999) Cytotoxicity of HuaChanSu on three digestive tract tumour cells in vitro. Chinese Med Pharma Clin 15: 28-29